Epigenic Therapeutics to Initiate Clinical Development of EPI-003
This first-in-human study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EPI-003 in Nucleos(t)ide Analogue-Treated, Chronic Hepatitis B Patients.
Pharmacokinetics | 20/11/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy